These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31471165)

  • 1. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?
    Fini MA; Stenmark KR
    Eur J Intern Med; 2019 Nov; 69():e11-e12. PubMed ID: 31471165
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
    Hershfield MS; Roberts LJ; Ganson NJ; Kelly SJ; Santisteban I; Scarlett E; Jaggers D; Sundy JS
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14351-6. PubMed ID: 20660758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
    Johnson RJ; Choi HK; Yeo AE; Lipsky PE
    Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegloticase (krystexxa) for treatment of refractory gout.
    Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
    [No Abstract]   [Full Text] [Related]  

  • 6. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
    Schlesinger N; Lipsky PE
    Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    Yeter KC; Ortiz EC; Arkfeld DG
    Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
    [No Abstract]   [Full Text] [Related]  

  • 9. Pegloticase.
    Schlesinger N; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Jan; 10(1):17-8. PubMed ID: 21193861
    [No Abstract]   [Full Text] [Related]  

  • 10. Pegloticase for chronic gout.
    Anderson A; Singh JA
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of gouty tophi after twelve weeks of pegloticase treatment.
    Baraf HS; Matsumoto AK; Maroli AN; Waltrip RW
    Arthritis Rheum; 2008 Nov; 58(11):3632-4. PubMed ID: 18975338
    [No Abstract]   [Full Text] [Related]  

  • 13. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
    Bessen SY; Bessen MY; Yung CM
    Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
    Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
    Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of biotechnological drugs in the treatment of gout.
    Cavagna L; Taylor WJ
    Biomed Res Int; 2014; 2014():264859. PubMed ID: 24839602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.
    Modjinou DV; Krasnokutsky S; Gyftopoulos S; Pike VC; Karis E; Keenan RT; Lee K; Crittenden DB; Samuels J; Pillinger MH
    Clin Rheumatol; 2017 Sep; 36(9):2101-2107. PubMed ID: 28623421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.